Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

Pfiz­er and Mer­ck KGaA have de­tailed the Phase III da­ta that in­spired FDA reg­u­la­tors to des­ig­nate Baven­cio a “break­through” for first-line ad­vanced blad­der can­cer and of­fered an ear­ly glance at how the PD-L1 can help pa­tients with a rare gy­ne­co­log­i­cal can­cer — carv­ing out nich­es in the check­point space for it­self af­ter be­ing shut out of nu­mer­ous oth­ers.

In JAVELIN Blad­der 100, Baven­cio led to a 31% re­duc­tion in risk of death com­pared to stan­dard care alone. It al­so ex­tend­ed me­di­an sur­vival by more than sev­en months — a his­toric feat in this set­ting, ac­cord­ing to in­ves­ti­ga­tors at Queen Mary Uni­ver­si­ty of Lon­don.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.